Page 1

Madrigal Pharmaceuticals Madrigal Pharmaceuticals Provides Corporate Update and Reports 2021 Third Quarter Financial Results November 4 , 2021 Several abstracts with data from the open - label arm of the Phase 3 MAESTRO - NAFLD - 1 study accepted for presentation at AASLD's upcoming The Liver MeetingⓇ 2021 CONSHOHOCKEN , Pa . , Nov. 04 , 2021 ( GLOBE NEWSWIRE ) -- Madrigal Pharmaceuticals , Inc. ( NASDAQ : MDGL ) today provides a summary of corporate accomplishments and reports its third quarter 2021 financial results . Paul Friedman , M.D. , Chief Executive Officer of Madrigal , stated , " Throughout the third quarter , the Madrigal team continued to progress MAESTRO - NASH , the pivotal serial liver biopsy study and a key component of the Phase 3 program for resmetirom for patients with non - alcoholic steatohepatitis , NASH . We remain on track to complete the double - blind portion of our Phase 3 non - invasive imaging and biomarker study , MAESTRO - NAFLD - 1 , and report topline data by year - end , with additional topline data rollout in early 2022. We will also be presenting additional data from the open - label portion of this study at the American Association for the Study of Liver Diseases ( AASLD ) The Liver MeetingⓇ on November 12-15th " Becky Taub , M.D. , Chief Medical Officer and President of Research & Development at Madrigal stated , “ Data from the recently completed 52 week open - label arm of the MAESTRO - NAFLD - 1 study will be presented at AASLD and provides our most informed insights to date regarding the effects of resmetirom in presumed NASH patients , using a variety of non - invasive tests relevant to clinical practice . The double - blinded MAESTRO - NAFLD - 1 and MAESTRO NASH studies readouts over the forthcoming months will further inform our understanding of how to identify and monitor NASH patients with significant fibrosis . " Dr. Taub added , " In October , in recognition of Liver Awareness Month , we announced our alliance with the Fatty Liver Foundation , a leading patient advocacy organization focused on the diagnosis , treatment and support of individuals with non - alcoholic fatty liver disease or NAFLD and NASH . Our alliance with the Foundation is in support of their NAFLD Screening Fund and aligns with our commitment to advance the use of non - invasive techniques to improve the diagnosis and staging of NAFLD and NASH and identify people at risk of NASH earlier in the course of their disease . ” Several abstracts summarizing data from the open - label arms of the MAESTRO - NAFLD - 1 study have been accepted for presentation at AASLD's The Liver MeetingⓇ 2021. Madrigal will host a webcast and conference call on Tuesday , November 16th at 8.00 AM ET to summarize and discuss the data that are being presented . AASLD Presentations • Friday , November 12 , 2021 : Late - breaker Poster Presentation ( abstract # LP21 )